Psyence Biomedical Ltd. (PBM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Jun 22, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PBM SEC filings page.
This page shows Psyence Biomedical Ltd. (PBM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing inflows currently support large operating cash outflows while reported revenue remains unavailable.
In FY2025 and FY2026, operating cash flow stayed negative while financing cash flow was positive and larger, so balance-sheet expansion reflects funding activity rather than internally generated cash. In FY2026, the net loss of$6.9M was close to the operating cash outflow of$8.1M , making cash needs more informative than the earnings swing alone.
Liabilities exceeded assets in FY2023, but by FY2026 the company reported
FY2026 free cash flow nearly matched operating cash flow, while investing cash flow was negative; the company was consuming cash both to run operations and fund investments. The reported liquidity comparison equaled 11 months of the latest annual operating outflow, alongside financing inflows that exceeded operating cash outflow.
Financial Health Signals
Psyence Biomedical Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Psyence Biomedical Ltd. passes 0 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Psyence Biomedical Ltd. reported a net loss of $6.9M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Psyence Biomedical Ltd. reported -$753K in net income in Q1 2026. This represents a decrease of 632.4% from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Cash & Balance Sheet
Psyence Biomedical Ltd. held $7.1M in cash as of Q1 2026; long-term debt is not reported for that period.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Psyence Biomedical Ltd.'s ROE was -6.3% in Q1 2026, measuring profit generated per dollar of shareholder equity.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Capital Allocation
None of these metrics is reported for Q1 2026.
PBM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Income Tax, EPS (Basic), EPS (Diluted).
PBM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'266-K | Q3'256-K | Q1'256-K | Q3'2420-F | Q1'2410-Q | Q3'2310-Q | Q3'2210-Q |
|---|---|---|---|---|---|---|---|
| Total Assets | $12.8M+468.5% | $7.3M+546.2% | $2.3M | $1.1M-28.8% | N/A | $1.6M-13.1% | $1.8M |
| Current Assets | $7.6M+240.1% | $6.6M+482.3% | $2.2M | $1.1M-29.2% | N/A | $1.6M-13.1% | $1.8M |
| Cash & Equivalents | $7.1M+270.0% | $6.1M+736.8% | $1.9M+219.2% | $733K-45.0% | $605K | $1.3M-23.9% | $1.8M |
| Total Liabilities | $943K-73.1% | $594K-95.1% | $3.5M | $12.1M+576.0% | N/A | $1.8M+1260.3% | $132K |
| Long-Term Debt | N/A | N/A | N/A | $10.4M | N/A | N/A | N/A |
| Total Equity | $11.9M+1045.5% | $6.7M+161.3% | -$1.3M-27.7% | -$11.0M-5374.1% | -$983K | -$200K-111.8% | $1.7M |
| Retained Earnings | -$58.4M-7.2% | -$56.4M+1.8% | -$54.5M | -$57.5M-812.1% | N/A | -$6.3M-103.6% | -$3.1M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Current Liabilities, Non-Current Liabilities.
PBM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
PBM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Psyence Biomedical Ltd. PBM | FY2026 | N/A | -$6.9M | N/A | $19.5M | — |
| Scinai Immunotherapeutics Ltd. SCNI | FY2025 | $1.3M | -$8.3M | N/A | $766K | 46/100 |
| Salarius Pharmaceuticals, Inc. SLRX | FY2025 | N/A | $12.5M | N/A | $4.9M | — |
| GT Biopharma Inc. GTBP | FY2025 | N/A | -$28.4M | N/A | $11.2M | — |
| PROTAGENIC THERAPEUTICS PTIX | FY2026 | $0 | $1.4M | N/A | $1.4M | — |
| Virax Biolabs Group Limited VRAX | FY2026 | $12K | -$5.0M | N/A | $1.7M | — |
Where Psyence Biomedical Ltd. Ranks
Frequently Asked Questions
Is Psyence Biomedical Ltd. profitable?
No, Psyence Biomedical Ltd. (PBM) reported a net income of -$6.9M in fiscal year 2026.
What is Psyence Biomedical Ltd.'s return on equity (ROE)?
Psyence Biomedical Ltd. (PBM) has a return on equity of -40.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Psyence Biomedical Ltd.'s free cash flow?
Psyence Biomedical Ltd. (PBM) recorded an outflow of $8.1M in free cash flow during fiscal year 2026. This represents a -117.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Psyence Biomedical Ltd.'s operating cash flow?
Psyence Biomedical Ltd. (PBM) recorded an outflow of $8.1M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Psyence Biomedical Ltd.'s total assets?
Psyence Biomedical Ltd. (PBM) had $17.6M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Psyence Biomedical Ltd.'s capital expenditures?
Psyence Biomedical Ltd. (PBM) invested $229 in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Psyence Biomedical Ltd.'s debt-to-equity ratio?
Psyence Biomedical Ltd. (PBM) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Psyence Biomedical Ltd.'s return on assets (ROA)?
Psyence Biomedical Ltd. (PBM) had a return on assets of -39.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Psyence Biomedical Ltd.'s P/E ratio?
Psyence Biomedical Ltd. (PBM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $19.5M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Psyence Biomedical Ltd.'s price-to-sales ratio?
Psyence Biomedical Ltd. (PBM) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $19.5M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Psyence Biomedical Ltd.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Psyence Biomedical Ltd. (PBM) held $7.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.1M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Psyence Biomedical Ltd.'s Piotroski F-Score?
Psyence Biomedical Ltd. (PBM) has a Piotroski F-Score of 0 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Psyence Biomedical Ltd.'s earnings high quality?
Psyence Biomedical Ltd. (PBM) reported a net loss of $6.9M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.